Pulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternatives

January 8, 2024

https://www.prnewswire.com/news-releases/pulmatrix-announces-stopping-the-pur1900-phase-2b-study-patient-enrollment-and-closing-the-study-in-agreement-with-partner-cipla-to-preserve-cash-and-facilitate-pursuit-of-strategic-alternatives-302027934.html

Cipla to take sole responsibility for development of PUR1900, refocused on markets with greatest unmet need and faster path to approval, in exchange for 2% royalty on net sales payable to Pulmatrix 

Read more at prnewswire.com

Related news for (PULM)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.